Condition: Critical Illness · Intensive Care Patients · Critical Illness Requiring Intensive Care - Sepsis · Sponsor: Assistance Publique - Hôpitaux de Paris
This is a prospective observational physiopathological study aimed at evaluating the immunological and inflammatory determinants associated with the prognosis of patients admitted to intensive care units (ICU). The study will establish multidimensional models predicting one-year survival and the occurrence of nosocomial infections. Patients admitted to ICU undergo routine biological sampling. In addition to these, minimal supplementary samples will be collected for immunological and inflammatory biomarker analysis at admission, day 1, day 4, day 8, ICU discharge or day 28, and at 12 months. Additional samples may be taken during clinically significant events (nosocomial infections, complications).
This description comes directly from the study's public registry record.
Charles de de Roquetaillade, MD · +33 1 49 95 85 15 · charles.de-roquetaillade@aphp.fr
Benjamin Glenn Chousterman, MD PhD · +33 1 49 95 85 15 · benjamin.chousterman@aphp.fr
Always discuss trial participation with your own doctor first.
| AP-HP Laribosière Hospital, Anesthesia and Critical Care Departement | Paris, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07345169